NCT06357845 Linking Somatic Mutation Rate With Baseline Exposure in East Palestine
| NCT ID | NCT06357845 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Somatic Mutation |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-08-16 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2024-08-16 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to This research team is conducting this study to develop methods to measure the biological impact of exposure to the chemicals released following the February 3, 2023 train derailment on residents of East Palestine, Ohio, and surrounding communities. The main question it aims to answer is: * What biological impact will be measured based on DNA damage? * In participants who provide a biospecimen, how are biomarker changes related to proximity to the derailment and variations in residents' health histories and behaviors? Participants will: * Complete a brief survey asking about experiences related to the February 3, 2023 train derailment, health experiences, and concerns following the derailment, and background information regarding health history. * Possibly contribute biospecimens such as blood, spit, hair, and/or toenail clippings. * Receive communication about study updates and future research opportunities. * A total of 40 study participants will be recruited to participate in a 90-minute interview. The interviews will be video and audio recorded.
Eligibility Criteria
Inclusion Criteria: * Residence on February 3rd, 2023 in Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, PA, or Lawrence County, PA. * Current residence in the United States. Exclusion Criteria: * Address provided for February 3rd, 2023 not in Columbiana County, Ohio, Mahoning County, Ohio, Beaver County, PA, or Lawrence County, PA * Invalid address provided for February 3rd, 2023 residence.
Contact & Investigator
Fredrick R Schumacher, PhD
PRINCIPAL INVESTIGATOR
Case Western Reserve University, Case Comprehensive Cancer Center
Frequently Asked Questions
Who can join the NCT06357845 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Somatic Mutation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06357845 currently recruiting?
Yes, NCT06357845 is actively recruiting participants. Contact the research team at healthyfutures@case.edu for enrollment information.
Where is the NCT06357845 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT06357845 clinical trial?
NCT06357845 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Fredrick R Schumacher, PhD at Case Western Reserve University, Case Comprehensive Cancer Center. The trial plans to enroll 500 participants.